Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(4):558–564. doi: 10.1054/bjoc.2000.1641

Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion

C Fujiyama 1,3, A Jones 1,2,3, S Fuggle 3, R Bicknell 1, D Cranston 2, A L Harris 1
PMCID: PMC2363759  PMID: 11207054

Abstract

As well as being a passive support, the extracellular matrix also regulates key biological processes such as invasion, differentiation and angiogenesis. We have therefore developed an in vitro model of bladder cancer invasion using de-epithelialized rat bladder to allow for tumour cell–extracellular matrix interactions. Onto this we have seeded a panel of human bladder cancer cell lines (RT4, RT112, 253J and EJ28 (T24)) representing progression from well to poorly differentiated phenotypes and used as models of superficial to invasive bladder cancer. The better differentiated cell lines RT4 and RT112 reproducibly grew as stratified epithelium, whereas poorly differentiated EJ28 cells invaded across a broad front. Invasion was not simply related to proliferation rate, measured either as doubling time on plastic (non-invasive 253J and invasive EJ28 having the same doubling time) or by Ki-67 proliferation index within the model. We used the model to test the ability of 4 compounds that interfere with tumour cell–extracellular matrix interactions (suramin, N-acetylcysteine and the urokinase plasminogen activator pathway antagonists Å5 compound and monoclonal antibody Mab 3936) to inhibit invasion. At non-toxic concentrations, all significantly inhibited invasion (P< 0.05), although to varying degrees, suramin and Å5 almost completely and N-acetylcysteine the least. In conclusion, this model shows the urokinase system is important for bladder invasion and can be used to investigate other mechanisms of bladder cancer invasion and also for the testing of intravesical drugs. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: invasion, in vitro assay, bladder cancer, suramin, N-acetylcysteine

Full Text

The Full Text of this article is available as a PDF (438.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albini A., D'Agostini F., Giunciuglio D., Paglieri I., Balansky R., De Flora S. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int J Cancer. 1995 Mar 29;61(1):121–129. doi: 10.1002/ijc.2910610121. [DOI] [PubMed] [Google Scholar]
  2. Bajou K., Noël A., Gerard R. D., Masson V., Brunner N., Holst-Hansen C., Skobe M., Fusenig N. E., Carmeliet P., Collen D. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998 Aug;4(8):923–928. doi: 10.1038/nm0898-923. [DOI] [PubMed] [Google Scholar]
  3. Behrendt N., Rønne E., Danø K. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J Biol Chem. 1993 Mar 15;268(8):5985–5989. [PubMed] [Google Scholar]
  4. Bhat G. J., Gunaje J. J., Idell S. Urokinase-type plasminogen activator induces tyrosine phosphorylation of a 78-kDa protein in H-157 cells. Am J Physiol. 1999 Aug;277(2 Pt 1):L301–L309. doi: 10.1152/ajplung.1999.277.2.L301. [DOI] [PubMed] [Google Scholar]
  5. Booth C., Harnden P., Trejdosiewicz L. K., Scriven S., Selby P. J., Southgate J. Stromal and vascular invasion in an human in vitro bladder cancer model. Lab Invest. 1997 Jun;76(6):843–857. [PubMed] [Google Scholar]
  6. Borgström P., Bourdon M. A., Hillan K. J., Sriramarao P., Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate. 1998 Apr 1;35(1):1–10. doi: 10.1002/(sici)1097-0045(19980401)35:1<1::aid-pros1>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  7. Brooks P. C., Strömblad S., Klemke R., Visscher D., Sarkar F. H., Cheresh D. A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995 Oct;96(4):1815–1822. doi: 10.1172/JCI118227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chern H. D., Becich M. J., Persad R. A., Romkes M., Smith P., Collins C., Li Y. H., Branch R. A. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins. J Urol. 1996 Nov;156(5):1846–1849. [PubMed] [Google Scholar]
  9. Conese M., Blasi F. The urokinase/urokinase-receptor system and cancer invasion. Baillieres Clin Haematol. 1995 Jun;8(2):365–389. doi: 10.1016/s0950-3536(05)80273-2. [DOI] [PubMed] [Google Scholar]
  10. Cook G. P., Hampton J. A. Effects of ibuprofen on the in vitro invasiveness of a human transitional cell carcinoma. Anticancer Res. 1997 Jan-Feb;17(1A):365–368. [PubMed] [Google Scholar]
  11. Crew J. P., O'Brien T., Bradburn M., Fuggle S., Bicknell R., Cranston D., Harris A. L. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997 Dec 1;57(23):5281–5285. [PubMed] [Google Scholar]
  12. Davies G., Jiang W. G., Mason M. D. Cell-cell adhesion molecules and their associated proteins in bladder cancer cells and their role in mitogen induced cell-cell dissociation and invasion. Anticancer Res. 1999 Jan-Feb;19(1A):547–552. [PubMed] [Google Scholar]
  13. Eisenberger M. A., Reyno L. M., Jodrell D. I., Sinibaldi V. J., Tkaczuk K. H., Sridhara R., Zuhowski E. G., Lowitt M. H., Jacobs S. C., Egorin M. J. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst. 1993 Apr 21;85(8):611–621. doi: 10.1093/jnci/85.8.611. [DOI] [PubMed] [Google Scholar]
  14. Elliott A. Y., Cleveland P., Cervenka J., Castro A. E., Stein N., Hakala T. R., Fraley E. E. Characterization of a cell line from human transitional cell cancer of the urinary tract. J Natl Cancer Inst. 1974 Nov;53(5):1341–1349. doi: 10.1093/jnci/53.5.1341. [DOI] [PubMed] [Google Scholar]
  15. Fadl-Elmula I., Gorunova L., Mandahl N., Elfving P., Lundgren R., Mitelman F., Heim S. Cytogenetic monoclonality in multifocal uroepithelial carcinomas: evidence of intraluminal tumour seeding. Br J Cancer. 1999 Sep;81(1):6–12. doi: 10.1038/sj.bjc.6690643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990 Jan 3;82(1):4–6. doi: 10.1093/jnci/82.1.4. [DOI] [PubMed] [Google Scholar]
  17. Fujiyama C., Masaki Z., Sugihara H. Reconstruction of the urinary bladder mucosa in three-dimensional collagen gel culture: fibroblast-extracellular matrix interactions on the differentiation of transitional epithelial cells. J Urol. 1995 Jun;153(6):2060–2067. [PubMed] [Google Scholar]
  18. Gilbert H. A., Logan J. L., Kagan A. R., Friedman H. A., Cove J. K., Fox M., Muldoon T. M., Lonni Y. W., Rowe J. H., Cooper J. F. The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading. J Urol. 1978 Apr;119(4):488–492. doi: 10.1016/s0022-5347(17)57526-6. [DOI] [PubMed] [Google Scholar]
  19. Grøndahl-Hansen J., Christensen I. J., Briand P., Pappot H., Mouridsen H. T., Blichert-Toft M., Danø K., Brünner N. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res. 1997 Feb;3(2):233–239. [PubMed] [Google Scholar]
  20. Habuchi T., Takahashi R., Yamada H., Kakehi Y., Sugiyama T., Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet. 1993 Oct 30;342(8879):1087–1088. doi: 10.1016/0140-6736(93)92066-3. [DOI] [PubMed] [Google Scholar]
  21. Harris A. L., Neal D. E. Bladder cancer--field versus clonal origin. N Engl J Med. 1992 Mar 12;326(11):759–761. doi: 10.1056/NEJM199203123261108. [DOI] [PubMed] [Google Scholar]
  22. Hasui Y., Marutsuka K., Nishi S., Kitada S., Osada Y., Sumiyoshi A. The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol. 1994 Jan;151(1):16–20. doi: 10.1016/s0022-5347(17)34861-9. [DOI] [PubMed] [Google Scholar]
  23. Hudson M. A., McReynolds L. M. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. J Natl Cancer Inst. 1997 May 21;89(10):709–717. doi: 10.1093/jnci/89.10.709. [DOI] [PubMed] [Google Scholar]
  24. Irani K., Xia Y., Zweier J. L., Sollott S. J., Der C. J., Fearon E. R., Sundaresan M., Finkel T., Goldschmidt-Clermont P. J. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 1997 Mar 14;275(5306):1649–1652. doi: 10.1126/science.275.5306.1649. [DOI] [PubMed] [Google Scholar]
  25. Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993 Apr 29;362(6423):841–844. doi: 10.1038/362841a0. [DOI] [PubMed] [Google Scholar]
  26. Lamm D. L., Griffith J. G. Intravesical therapy: does it affect the natural history of superficial bladder cancer? Semin Urol. 1992 Feb;10(1):39–44. [PubMed] [Google Scholar]
  27. Liotta L. A., Rao C. N., Barsky S. H. Tumor invasion and the extracellular matrix. Lab Invest. 1983 Dec;49(6):636–649. [PubMed] [Google Scholar]
  28. Ma D., Gerard R. D., Li X. Y., Alizadeh H., Niederkorn J. Y. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood. 1997 Oct 1;90(7):2738–2746. [PubMed] [Google Scholar]
  29. Miyake H., Yoshimura K., Hara I., Eto H., Arakawa S., Kamidono S. Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J Urol. 1997 Jun;157(6):2351–2355. [PubMed] [Google Scholar]
  30. O'Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997 Jan 24;88(2):277–285. doi: 10.1016/s0092-8674(00)81848-6. [DOI] [PubMed] [Google Scholar]
  31. Oshinsky G. S., Chen Y., Jarrett T., Anderson A. E., Weiss G. H. A model of bladder tumor xenografts in the nude rat. J Urol. 1995 Nov;154(5):1925–1929. [PubMed] [Google Scholar]
  32. Ossowski L. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res. 1992 Dec 15;52(24):6754–6760. [PubMed] [Google Scholar]
  33. Ossowski L., Russo-Payne H., Wilson E. L. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res. 1991 Jan 1;51(1):274–281. [PubMed] [Google Scholar]
  34. Parada L. F., Tabin C. J., Shih C., Weinberg R. A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature. 1982 Jun 10;297(5866):474–478. doi: 10.1038/297474a0. [DOI] [PubMed] [Google Scholar]
  35. Pedersen H., Brünner N., Francis D., Osterlind K., Rønne E., Hansen H. H., Danø K., Grøndahl-Hansen J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 1994 Sep 1;54(17):4671–4675. [PubMed] [Google Scholar]
  36. Pesenti E., Sola F., Mongelli N., Grandi M., Spreafico F. Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Br J Cancer. 1992 Aug;66(2):367–372. doi: 10.1038/bjc.1992.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Pyke C., Kristensen P., Ralfkiaer E., Grøndahl-Hansen J., Eriksen J., Blasi F., Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 1991 May;138(5):1059–1067. [PMC free article] [PubMed] [Google Scholar]
  38. Raghavan D., Shipley W. U., Garnick M. B., Russell P. J., Richie J. P. Biology and management of bladder cancer. N Engl J Med. 1990 Apr 19;322(16):1129–1138. doi: 10.1056/NEJM199004193221607. [DOI] [PubMed] [Google Scholar]
  39. Rebel J. M., Thijssen C. D., Vermey M., Delouvée A., Zwarthoff E. C., Van der Kwast T. H. E-cadherin expression determines the mode of replacement of normal urothelium by human bladder carcinoma cells. Cancer Res. 1994 Oct 15;54(20):5488–5492. [PubMed] [Google Scholar]
  40. Redwood S. M., Liu B. C., Weiss R. E., Hodge D. E., Droller M. J. Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer. 1992 Mar 1;69(5):1212–1219. doi: 10.1002/cncr.2820690524. [DOI] [PubMed] [Google Scholar]
  41. Scriven S. D., Booth C., Thomas D. F., Trejdosiewicz L. K., Southgate J. Reconstitution of human urothelium from monolayer cultures. J Urol. 1997 Sep;158(3 Pt 2):1147–1152. doi: 10.1097/00005392-199709000-00115. [DOI] [PubMed] [Google Scholar]
  42. See W. A., Miller J. S., Williams R. D. Pathophysiology of transitional tumor cell adherence to sites of urothelial injury in rats: mechanisms mediating intravesical recurrence due to implantation. Cancer Res. 1989 Oct 1;49(19):5414–5418. [PubMed] [Google Scholar]
  43. Sidransky D., Frost P., Von Eschenbach A., Oyasu R., Preisinger A. C., Vogelstein B. Clonal origin bladder cancer. N Engl J Med. 1992 Mar 12;326(11):737–740. doi: 10.1056/NEJM199203123261104. [DOI] [PubMed] [Google Scholar]
  44. Skobe M., Rockwell P., Goldstein N., Vosseler S., Fusenig N. E. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med. 1997 Nov;3(11):1222–1227. doi: 10.1038/nm1197-1222. [DOI] [PubMed] [Google Scholar]
  45. Soloway M. S., Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer. 1980 Sep 1;46(5):1158–1163. doi: 10.1002/1097-0142(19800901)46:5<1158::aid-cncr2820460514>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  46. Southgate J., Hutton K. A., Thomas D. F., Trejdosiewicz L. K. Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest. 1994 Oct;71(4):583–594. [PubMed] [Google Scholar]
  47. Theodorescu D., Cornil I., Fernandez B. J., Kerbel R. S. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci U S A. 1990 Nov;87(22):9047–9051. doi: 10.1073/pnas.87.22.9047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Theodorescu D., Laderoute K. R., Gulding K. M. Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process. Cell Growth Differ. 1998 Nov;9(11):919–928. [PubMed] [Google Scholar]
  49. Wallace D. M., Smith J. H., Billington S., Smith M. R., Stemplewski H. E., Tipton P. W. Promotion of bladder tumours by endoscopic procedures in an animal model. Br J Urol. 1984 Dec;56(6):658–662. doi: 10.1111/j.1464-410x.1984.tb06140.x. [DOI] [PubMed] [Google Scholar]
  50. Walther M. M., Figg W. D., Linehan W. M. Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World J Urol. 1996;14 (Suppl 1):S8–11. doi: 10.1007/BF00182057. [DOI] [PubMed] [Google Scholar]
  51. Yip L., Dart R. C., Hurlbut K. M. Intravenous administration of oral N-acetylcysteine. Crit Care Med. 1998 Jan;26(1):40–43. doi: 10.1097/00003246-199801000-00014. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES